Concord Biotech Limited (BOM:543960)
India
· Delayed Price · Currency is INR 1,177.30
-29.00 (-2.40%)
At close: Mar 9, 2026
Concord Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Revenue | 11,587 | 12,001 | 10,169 | 8,532 | 7,129 | 6,169 | Upgrade
|
| Revenue Growth (YoY) | 6.38% | 18.01% | 19.20% | 19.67% | 15.56% | 20.42% | Upgrade
|
| Cost of Revenue | 4,181 | 4,317 | 3,498 | 1,921 | 1,719 | 1,169 | Upgrade
|
| Gross Profit | 7,406 | 7,684 | 6,672 | 6,611 | 5,410 | 5,000 | Upgrade
|
| Selling, General & Admin | 1,681 | 1,389 | 1,230 | 1,103 | 956.96 | 694.73 | Upgrade
|
| Other Operating Expenses | 1,250 | 1,150 | 1,038 | 1,969 | 1,662 | 1,001 | Upgrade
|
| Operating Expenses | 3,627 | 3,083 | 2,805 | 3,612 | 3,120 | 1,976 | Upgrade
|
| Operating Income | 3,779 | 4,601 | 3,867 | 2,999 | 2,290 | 3,024 | Upgrade
|
| Interest Expense | -2.95 | -5.29 | -25.52 | -45.1 | -54.84 | -6.66 | Upgrade
|
| Interest & Investment Income | 17.1 | 17.1 | 30.41 | 44.41 | 47.87 | 17.87 | Upgrade
|
| Earnings From Equity Investments | 15.36 | -13.22 | 33.71 | 19.59 | -36.38 | -4.49 | Upgrade
|
| Currency Exchange Gain (Loss) | 81.98 | 81.98 | 64.81 | 102.22 | 63.59 | 15.51 | Upgrade
|
| Other Non Operating Income (Expenses) | 62.97 | 43.54 | 12.79 | 57.93 | 9.73 | 11.25 | Upgrade
|
| EBT Excluding Unusual Items | 3,954 | 4,725 | 3,983 | 3,178 | 2,320 | 3,057 | Upgrade
|
| Gain (Loss) on Sale of Investments | 222.64 | 222.64 | 140.65 | 37.17 | 52.3 | 69.86 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.25 | -2.25 | 0.12 | -0.94 | -0.34 | - | Upgrade
|
| Other Unusual Items | -32.75 | - | - | -0.31 | - | - | Upgrade
|
| Pretax Income | 4,141 | 4,946 | 4,126 | 3,220 | 2,375 | 3,127 | Upgrade
|
| Income Tax Expense | 1,030 | 1,229 | 1,045 | 819.28 | 625.89 | 778.33 | Upgrade
|
| Net Income | 3,125 | 3,716 | 3,081 | 2,401 | 1,749 | 2,349 | Upgrade
|
| Net Income to Common | 3,125 | 3,716 | 3,081 | 2,401 | 1,749 | 2,349 | Upgrade
|
| Net Income Growth | -4.22% | 20.62% | 28.33% | 37.25% | -25.53% | 38.89% | Upgrade
|
| Shares Outstanding (Basic) | 105 | 105 | 105 | 105 | 105 | 105 | Upgrade
|
| Shares Outstanding (Diluted) | 105 | 105 | 105 | 105 | 105 | 105 | Upgrade
|
| EPS (Basic) | 29.69 | 35.52 | 29.45 | 22.95 | 16.72 | 22.45 | Upgrade
|
| EPS (Diluted) | 29.69 | 35.52 | 29.45 | 22.95 | 16.72 | 22.45 | Upgrade
|
| EPS Growth | -4.82% | 20.62% | 28.33% | 37.25% | -25.52% | 38.88% | Upgrade
|
| Free Cash Flow | - | 1,333 | 1,798 | 1,009 | 526.36 | -373.59 | Upgrade
|
| Free Cash Flow Per Share | - | 12.75 | 17.18 | 9.65 | 5.03 | -3.57 | Upgrade
|
| Dividend Per Share | - | 10.700 | 8.750 | 6.830 | 5.120 | 6.741 | Upgrade
|
| Dividend Growth | - | 22.29% | 28.11% | 33.40% | -24.05% | 63.87% | Upgrade
|
| Gross Margin | 63.91% | 64.03% | 65.61% | 77.49% | 75.89% | 81.05% | Upgrade
|
| Operating Margin | 32.62% | 38.34% | 38.03% | 35.15% | 32.12% | 49.01% | Upgrade
|
| Profit Margin | 26.97% | 30.97% | 30.30% | 28.14% | 24.54% | 38.07% | Upgrade
|
| Free Cash Flow Margin | - | 11.11% | 17.68% | 11.83% | 7.38% | -6.06% | Upgrade
|
| EBITDA | 4,311 | 5,127 | 4,386 | 3,527 | 2,778 | 3,287 | Upgrade
|
| EBITDA Margin | 37.20% | 42.72% | 43.13% | 41.33% | 38.97% | 53.28% | Upgrade
|
| D&A For EBITDA | 531.75 | 526.08 | 518.51 | 527.85 | 487.98 | 263.27 | Upgrade
|
| EBIT | 3,779 | 4,601 | 3,867 | 2,999 | 2,290 | 3,024 | Upgrade
|
| EBIT Margin | 32.62% | 38.34% | 38.03% | 35.15% | 32.12% | 49.01% | Upgrade
|
| Effective Tax Rate | 24.86% | 24.85% | 25.32% | 25.44% | 26.35% | 24.89% | Upgrade
|
| Revenue as Reported | 12,051 | 12,445 | 10,507 | 8,885 | 7,364 | 6,308 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.